Used in research settings as a selective inhibitor of the MEK1/2 signaling pathway, AZ 628 helps investigate cell proliferation and survival mechanisms, particularly in cancer models. It is applied in studies targeting tumor growth, especially in cancers with RAS or RAF mutations, such as melanoma and non-small cell lung cancer. Its ability to cross the blood-brain barrier also makes it useful in exploring central nervous system involvement in oncogenic pathways. Additionally, AZ 628 is employed in combination studies with other kinase inhibitors to assess synergistic effects and overcome drug resistance.